This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release. The investigators will collect punch biopsies of lesional skin from HS patients before, and 1-2 months after botulinum toxin treatment (50U per axilla in 10 injections of 0.1mL) then perform flow cytometric, transcriptomic, and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes IL-17 driven skin inflammation.
Study Type
OBSERVATIONAL
Enrollment
20
Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States
RECRUITINGQuantification and phenotyping of skin resident dendritic cell, macrophage, and T cell populations in patients before and after intralesional Botox treatment.
immune cell phenotyping
Time frame: 1-2 months after first treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.